Article
Clinical Neurology
Edward E. Neuberger, Ibrahim M. Abbass, Eddie Jones, Natalie J. Engmann
Summary: This study evaluated work and activity impairment in patients with multiple sclerosis (MS) treated with ocrelizumab (OCR) versus other disease-modifying therapies (DMTs). The results showed that patients treated with OCR had higher odds of employment, lower overall work productivity loss, and lower activity impairment compared to those treated with other DMTs.
NEUROLOGY AND THERAPY
(2021)
Review
Clinical Neurology
Navid Manouchehri, Victor H. Salinas, Negar Rabi Yeganeh, David Pitt, Rehana Z. Hussain, Olaf Stuve
Summary: The effectiveness of disease modifying therapies (DMT) differs between different phenotypes of multiple sclerosis (MS), with progressive MS showing resistance. Immune senescence may explain this resistance.
FRONTIERS IN NEUROLOGY
(2022)
Article
Clinical Neurology
Patrick Vermersch, Celia Oreja-Guevara, Aksel Siva, Bart Van Wijmeersch, Heinz Wiendl, Jens Wuerfel, Regine Buffels, Karen Kadner, Thomas Kuenzel, Giancarlo Comi
Summary: The study showed that patients with relapsing-remitting multiple sclerosis receiving ocrelizumab treatment achieved a high rate of no evidence of disease activity (NEDA) over 96 weeks, especially for those primarily enrolled based on MRI activity. Patients with lower baseline EDSS scores and those receiving only one prior DMT treatment demonstrated higher rates of NEDA.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Medicine, General & Internal
Amit Bar-Or, Gian-Andrea Thanei, Christopher Harp, Corrado Bernasconi, Ulrike Bonati, Anne H. Cross, Saloumeh Fischer, Laura Gaetano, Stephen L. Hauser, Robert Hendricks, Ludwig Kappos, Jens Kuhle, David Leppert, Fabian Model, Annette Sauter, Harold Koendgen, Xiaoming Jia, Ann E. Herman
Summary: Baseline NfL levels are associated with brain atrophy, lesion expansion, and clinical progression in MS patients. Ocrelizumab treatment reduces NfL levels and eliminates the predictive value of baseline NfL on disability progression. Elevated NfL levels following ocrelizumab treatment may predict increased risk for clinical progression.
Review
Immunology
Georges Jalkh, Rachelle Abi Nahed, Gabrielle Macaron, Mary Rensel
Summary: In the past decade, the therapeutic options for multiple sclerosis have greatly expanded, with newer and more effective disease modifying therapies being increasingly used early in the disease course. Despite their advantages in controlling disease activity and improving long-term outcomes, these newer therapies come with safety concerns and monitoring requirements that highlight the need for periodic re-evaluation and adjustment of monitoring strategies for optimizing treatment safety in an individualized manner.
Review
Clinical Neurology
Francesca Washington, Dawn Langdon
Summary: Research shows that patients with multiple sclerosis often struggle with treatment adherence, influenced by factors such as age, gender, emotions, cognition, and treatment satisfaction. Targeted patient support programs should be developed to improve treatment compliance.
JOURNAL OF NEUROLOGY
(2022)
Review
Clinical Neurology
Antonios Bayas, Monika Christ, Simon Faissner, Juliane Klehmet, Refik Pul, Thomas Skripuletz, Sven G. Meuth, SPMS Working Group
Summary: Although the understanding of SPMS is evolving, early detection of relapse-independent progression remains difficult. The term RMS includes RRMS and SPMS with relapses, and disease-modifying therapies approved for RMS or active SPMS are used. However, there are differences in efficacy and safety evidence between drugs approved for RMS and SPMS. Clinical trials have shown that siponimod and interferon-beta 1b s.c. have significant reductions in disability progression in SPMS populations, but data on other drugs approved for RMS are limited to small subgroups and the potential to reduce relapse-independent progression is unclear.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2023)
Article
Clinical Neurology
Steve Simpson-Yap, Edward De Brouwer, Tomas Kalincik, Nick Rijke, Jan A. Hillert, Clare Walton, Gilles Edan, Yves Moreau, Tim Spelman, Lotte Geys, Tina Parciak, Clement Gautrais, Nikola Lazovski, Ashkan Pirmani, Amin Ardeshirdavanai, Lars Forsberg, Anna Glaser, Robert McBurney, Hollie Schmidt, Arnfin B. Bergmann, Stefan Braune, Alexander Stahmann, Rodden Middleton, Amber Salter, Robert J. Fox, Anneke van der Walt, Helmut Butzkueven, Raed Alroughani, Serkan Ozakbas, Juan Rojas, Ingrid van der Mei, Nupur Nag, Rumen Ivanov, Guilherme Sciascia do Olival, Alice Estavo Dias, Melinda Magyari, Doralina Brum, Maria Fernanda Mendes, Ricardo N. Alonso, Richard S. Nicholas, Johana Bauer, Anibal Sebastian Chertcoff, Anna Zabalza, Georgina Arrambide, Alexander Fidao, Giancarlo Comi, Liesbet Peeters
Summary: Using data from 12 sources in 28 countries, this study examined the characteristics of COVID-19 severity in people with MS, particularly those taking immunosuppressive therapies. The results showed that older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Additionally, rituximab was consistently associated with increased risk of hospitalization, ICU admission, and need for ventilation, while ocrelizumab was mainly associated with hospitalization and ICU admission.
Article
Clinical Neurology
Dejan Jakimovski, Katelyn S. Kavak, Caila B. Vaughn, Andrew D. Goodman, Patricia K. Coyle, Lauren Krupp, Malcolm Gottesman, Keith R. Edwards, Michael Lenihan, Allan Perel, Robert Zivadinov, Bianca Weinstock-Guttman
Summary: The study assessed the clinical course after treatment discontinuation in MS patients with long disease duration and found that patients with stable disease course might experience disability worsening after discontinuation, with no clear relation to age and disease subtype. Patients with EDSS >= 6.0 are at higher risk for disability worsening after discontinuation.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Clinical Neurology
Samantha Epstein, Kathryn T. Fong, Philip L. De Jager, Libby Levine, Claire Riley, Sarah Wesley, Wendy S. Vargas, Rebecca Farber
Summary: The study found no significant difference in clinical endpoints for patients over 55 receiving ocrelizumab compared to the control group before anti-CD20 therapy. However, due to the small sample size, a modest effect cannot be ruled out. Larger trials are needed to evaluate the use of ocrelizumab in this understudied subpopulation of MS.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Review
Clinical Neurology
Hans-Peter Hartung, Sven G. Meuth, Deborah M. Miller, Giancarlo Comi
Summary: The review assesses the reasons for considering discontinuation of disease-modifying therapies in MS patients, finding that stopping treatment may be feasible for older individuals with stable disease. Prognostic factors have been identified, and several clinical scenarios provide rationale for stopping treatment. Recent evidence allows for a more precise weighing of risks against benefits.
CURRENT OPINION IN NEUROLOGY
(2021)
Article
Clinical Neurology
Clara G. Chisari, Assunta Bianco, Vincenzo Brescia Morra, Massimiliano Calabrese, Fioravante Capone, Paola Cavalla, Carlotta Chiavazza, Cristoforo Comi, Maura Danni, Massimo Filippi, Pietro Iaffaldano, Roberta Lanzillo, Salvatore Lo Fermo, Alessandra Lucisano, Alessandra Lugaresi, Giacomo Lus, Gerolama Alessandra Marfia, Fabiana Marinelli, Massimiliano Mirabella, Lucia Moiola, Chiara Perin, Sabrina Realmuto, Simona Toscano, Maria Trojano, Domizia Vecchio, Francesco Patti, Italian MS Registry
Summary: This study evaluated the clinical effectiveness of ocrelizumab in patients with primary progressive multiple sclerosis (PPMS). The results showed that age over 65 years was associated with a higher risk of confirmed EDSS worsening at 24 months. The study suggests that patients who do not meet the ORATORIO criteria may still benefit from ocrelizumab treatment.
Article
Clinical Neurology
Luis A. Rodriguez de Antonio, Ines Cuberta-Gonzalez, Inmaculada Garcia-Castanon, Celia Oreja-Guevara
Summary: This study compared the clinical and radiological effectiveness of ocrelizumab in PPMS and RRMS patients, and found that ocrelizumab was effective in reducing relapses and MRI activity. The most common adverse events were infusion-related reactions, infections, and hematological side effects.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Review
Pharmacology & Pharmacy
Peter Alping
Summary: This study aimed to summarize the current evidence for rituximab as a treatment for relapsing-remitting MS (RRMS).
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
(2023)
Article
Clinical Neurology
Massimo Filippi, Maria Pia Amato, Diego Centonze, Paolo Gallo, Claudio Gasperini, Matilde Inglese, Francesco Patti, Carlo Pozzilli, Paolo Preziosa, Maria Trojano
Summary: Early intervention with high-efficacy disease-modifying therapies (HE-DMTs) can significantly reduce inflammation and disease progression in patients with multiple sclerosis (MS), with acceptable long-term safety risks.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Alexandra Buehler, Marcel Wolbers, Fabian Model, Qing Wang, Shibeshih Belachew, Marianna Manfrini, Johannes Lorscheider, Ludwig Kappos, Jan Beyersmann
Summary: This study proposes a definition of recurrent disability progression events and compares the analysis of time-to-first-event and recurrent events. The results show that recurrent event analysis includes a larger number of progression events, leading to more accurate treatment effect estimates and increased statistical power.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Menglan Pang, Audrey Gabelle, Paramita Saha-Chaudhuri, Willem Huijbers, Arie Gafson, Paul M. Matthews, Lu Tian, Ivana Rubino, Richard Hughes, Carl de Moor, Shibeshih Belachew, Changyu Shen
Summary: This study provides a proof of concept for precision medicine in future research and drug development for Alzheimer's disease through individual treatment response analysis.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Javier Villacieros-Alvarez, Carmen Espejo, Georgina Arrambide, Mireia Castillo, Pere Carbonell-Mirabent, Marta Rodriguez, Luca Bollo, Joaquin Castillo, Manuel Comabella, Ingrid Galan, Luciana Midaglia, Neus Mongay-Ochoa, Carlos Nos, Jordi Rio, Breogan Rodriguez-Acevedo, Jaume Sastre-Garriga, Carmen Tur, Angela Vidal-Jordana, Andreu Vilaseca, Ana Zabalza, Cristina Auger, Alex Rovira, Xavier Montalban, Mar Tintore, Alvaro Cobo-Calvo
Summary: MOG-Ab are rare in adults with a first demyelinating event suggestive of MS. However, it is suggested to determine these antibodies in patients with ON and absence of CSF-OBs based on the results.
ANNALS OF NEUROLOGY
(2023)
Article
Medical Laboratory Technology
David Wilson, Dandan Chan, Lei Chang, Robert Mathis, Inge Verberk, Xavier Montalban, Manuel Comabella, Nicolas Fissolo, Bibi Bielekova, Ruturaj Masvekar, Tanuja Chitnis, Tjalf Ziemssen, Katja Akguen, Kaj Blennow, Henrik Zetterberg, Wolfgang Brueck, Gavin Giovannoni, Sharmilee Gnanapavan, Stefan Bittner, Frauke Zipp, Giancarlo Comi, Roberto Furlan, Sylvain Lehmann, Simon Thebault, Mark Freedman, Amit Bar-Or, Marty Kramer, Markus Otto, Steffen Halbgebauer, Kevin Hrusovsky, Tatiana Plavina, Michael Khalil, Fredrik Piehl, Heinz Wiendl, Ludwig Kappos, Aleksandra Maceski, Eline Willemse, David Leppert, Charlotte Teunissen, Jens Kuhle
Summary: A fully automated digital immunoassay for measuring neurofilament light chain (NfL) in serum has been developed and validated across multiple centers. This assay shows high sensitivity, reproducibility, and automation, making it suitable for clinical use in assessing and monitoring axonal injury.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Article
Clinical Neurology
Alan J. Thompson, Marcello Moccia, Maria Pia Amato, Peter A. Calabresi, Marcia Finlayson, Annie Hawton, Fred D. Lublin, Ruth Ann Marrie, Xavier Montalban, Michael Panzara, Maria Pia Sormani, Jon Strum, Barbara G. Vickrey, Timothy Coetzee
Summary: The survey results show that stakeholders of multiple sclerosis (MS) believe that the current clinical course descriptors need to change and support a mechanism-driven framework for describing MS. Clinical validation and ease of communication with patients are the most important considerations when developing a new framework.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Amit Bar-Or, Anne H. Cross, Anthony L. Cunningham, Yann Hyvert, Andrea Seitzinger, Hans Guehring, Elise E. Drouin, Nektaria Alexandri, Davorka Tomic, Xavier Montalban
Summary: A post hoc analysis showed that Evobrutinib, an investigational drug for patients with relapsing multiple sclerosis (RMS), has an impact on immune responses. The results suggest that the drug acts as an immunomodulator, inhibiting aberrant immune cell responses while maintaining responsiveness to foreign and recall antigens.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Immunology
Nicolas Fissolo, Laura Calvo-Barreiro, Herena Eixarch, Ursula Boschert, Luisa M. Villar, Lucienne Costa-Frossard, Mireia Ferrer, Alex Sanchez, Eva Borras, Eduard Sabido, Carmen Espejo, Xavier Montalban, Manuel Comabella
Summary: This study characterized the transcriptomic and proteomic profiles induced by cladribine in blood cells, and identified potential treatment response biomarkers to cladribine in patients with multiple sclerosis.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Cell Biology
Sunny Malhotra, Mari Carmen Martin Miras, Agustin Pappolla, Xavier Montalban, Manuel Comabella
Summary: Liquid biopsy is a non-invasive method for studying early-stage biomarkers. It involves extracting and analyzing non-solid biological tissues without invasive procedures to determine disease prognosis. Liquid biopsy components, such as extracellular vesicles, microRNAs, and circulating tumor cells, have shown potential as valuable biomarkers in various neurological conditions. This review provides an overview of liquid biopsy and discusses its applications, future directions, and potential limitations.
Meeting Abstract
Clinical Neurology
Michael Barnett, Andrew Chan, Huiyu Feng, Kazuo Fujihara, Gavin Giovannoni, Ralf Gold, Xavier Montalban, Fu-Dong Shi, Maria Tintore, Qun Xue, Chunsheng Yang, Hongyu Zhou
MULTIPLE SCLEROSIS JOURNAL
(2023)
Review
Clinical Neurology
Ralf Gold, Michael Barnett, Andrew Chan, Huiyu Feng, Kazuo Fujihara, Gavin Giovannoni, Xavier Montalban, Fu-Dong Shi, Mar Tintore, Qun Xue, Chunsheng Yang, Hongyu Zhou
Summary: Dimethyl fumarate (DMF) is a widely used oral disease-modifying therapy for multiple sclerosis (MS) with proven efficacy and safety. Existing data on DMF are primarily derived from populations outside of Asia. However, recent approval for use in China suggests its relevance to the Chinese population as well.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2023)
Article
Clinical Neurology
Sara Sanchez-Velasco, Luciana Midaglia, Angela Vidal-Jordana, Felix Castillo, Rosalia Horno, Elena Carreras, Berta Serrano, Montserrat Bosch, Antonia Agusti, Xavier Montalban, Mar Tintore
Summary: Multiple sclerosis primarily affects women of childbearing age, making the pregnancy and postpartum period a topic of interest due to its impact on disease course and treatment considerations. This study reviews the safety of disease-modifying drugs during breastfeeding, including their transfer into breast milk and potential adverse effects on the infant. Interferon beta and glatiramer acetate are considered safe options during breastfeeding, while other drugs are not recommended. However, recent research suggests that some of these drugs may be used safely during this period.
REVISTA DE NEUROLOGIA
(2023)
Meeting Abstract
Clinical Neurology
Xavier Montalban, Jerry S. Wolinsky, Douglas L. Arnold, Martin S. Weber, Karolina Piasecka-Stryczynska, Davorka Tomic, Andrea Seitzinger, Hans Guehring
Meeting Abstract
Clinical Neurology
Carmen Tur, Zhaonan Sun, Daniel Bradley, Cynthia Grossman, Xavier Montalban, Alex Rovira, Mar Tintore, Nolan Campbell, Elizabeth Fisher
Meeting Abstract
Clinical Neurology
Marianna Cortese, Xiaojing Peng, Kjetil Bjornevik, Clary B. Clish, Gilles Edan, Mark Freedman, Hans-Peter Hartung, Xavier Montalban, Rupert Sandbrink, Ernst-Wilhelm Radue, Frederik Barkhof, Eva-Maria Wicklein, Ludwig Kappos, Kassandra Munger, Alberto Ascherio
Meeting Abstract
Clinical Neurology
X. Montalban, J. S. Wolinsky, D. L. Arnold, M. S. Weber, K. Piasecka-Stryczynska, D. Tomic, A. Seitzinger, H. Guehring
MULTIPLE SCLEROSIS JOURNAL
(2023)